Clinical Trial: Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder

Study Status: Terminated
Recruit Status: Unknown status
Study Type: Interventional

Official Title: The Dopaminergic System in Schizotypal Personality Disorder: Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder

Brief Summary:

Hypothesis: Schizotypal personality disorder patients will show cognitive improvements in 1) working memory 2) learning and memory 3) sustained attention 4) enhanced performance on the AX-CPT, N-back and Eriksen during pergolide treatment. There will be a significant diagnosis by drug administration of 0.3 mg of oral pergolide interaction for performance on the cognitive tasks, with the schizotypal personality disorder group demonstrating significantly improved peformance compared to the other personality disorder group after pergolide compared with placebo.

Design: Randomized, double-blind, crossover study of pergolide vs. placebo. Half of subjects receive pergolide for eight weeks; half of subjects receive placebo for four weeks followed by pergolide for four weeks.

Detailed Summary:
Sponsor: Bronx VA Medical Center

Current Primary Outcome: Performance on tests of sustained attention, episodic memory and working memory at baseline and after 2, 4, 6 and 8 weeks on the study medication

Original Primary Outcome: Same as current

Current Secondary Outcome: Hamilton Depression Rating Scale, Positive and Negative Symptom Scale and Clinical Global Impression scale at baseline and then weekly through the end of the trial

Original Secondary Outcome: Same as current

Information By: Bronx VA Medical Center

Dates:
Date Received: November 9, 2005
Date Started: October 2000
Date Completion:
Last Updated: November 17, 2005
Last Verified: November 2005